WEKO3
-
RootNode
アイテム
Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer
http://hdl.handle.net/10191/00051820
http://hdl.handle.net/10191/0005182085865a4d-b5b7-46ee-a21c-de72f1bafe50
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
本文 (1.1 MB)
|
|
|
|
要旨 (571.7 kB)
|
|
| Item type | 学位論文 / Thesis or Dissertation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2020-08-31 | |||||
| タイトル | ||||||
| タイトル | Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | glycogen synthase kinase-3 | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | renal cell carcinoma | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | apoptosis | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | cell cycle arrest | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | immune cells | |||||
| 資源タイプ | ||||||
| 資源 | http://purl.org/coar/resource_type/c_46ec | |||||
| タイプ | thesis | |||||
| その他のタイトル | ||||||
| その他のタイトル | 9-ING-41(GSK-3阻害剤)は、腎癌に対して単剤および併用療法として有効である | |||||
| 著者 |
Anraku, Tsutomu
× Anraku, Tsutomu |
|||||
| 著者別名 | ||||||
| 識別子Scheme | WEKO | |||||
| 識別子 | 178044 | |||||
| 姓名 | 安楽, 力 | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase, is involved in a broad range of pathological processes including cancer. GSK-3 has two isoforms, GSK-3αand GSK-3β, and GSK-3β has been recognized as a therapeutic target for the development of new anticancer drugs. The present study aimed to investigate the antitumor effects of9-ING-41, which is a maleimide-based ATP-competitive small molecule GSK-3β inhibitor active in patients with advanced cancer. In renal cancer cell lines, treatment with 9-ING-41 alone induced cell cycle arrest and apoptosis, and autophagy inhibitors increased the antitumor effects of 9-ING-41 when used in combination. Treatment with 9-ING-41 potentiated the antitumor effects of targeted therapeutics and increased the cytotoxic effects of cytokine-activated immune cells on renal cancer cell lines. These results provided a compelling rationale for the inclusion of patients with renal cancer in studies of 9-ING-41, both as a single agent and in combination with current standard therapies. | |||||
| 内容記述 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | International Journal of Molecular Medicine. 2020, 45(2), 315-323. | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | info:doi/10.3892/ijmm.2019.4427 | |||||
| 著者版フラグ | ||||||
| 値 | ETD | |||||
| 学位名 | ||||||
| 学位名 | 博士(医学) | |||||
| 学位授与機関 | ||||||
| 学位授与機関名 | 新潟大学 | |||||
| 学位授与年月日 | ||||||
| 学位授与年月日 | 2020-03-23 | |||||
| 学位授与番号 | ||||||
| 学位授与番号 | 13101甲第4697号 | |||||
| 学位記番号 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 新大院博(医)甲第931号 | |||||
